The Brigham and Women's Hospital, Inc.

Beth Israel Deaconess Medical Center, Inc.

Harvard College

US Government As Represented by the Secretary of the Army

Case Western Reserve University

Children's Medical Center Corporation

Gerald B Pier

Lisa Cavacini

Marshall R Posner

Casie Anne Kelly-Quintos

Nikolay Nifantiev

Marina Gening

Yury Tsvetkov

Michael J Preston

Lawrence C Madoff

Craig J Gerard

Ying Wang

Johannes Huebner

Julia Y Wang

Christoph Lange

Scott Weiss

David McKenney

Hara Levy

Jerald C Sadoff

John R Schreiber

Tomas Maira-Litran

Kimberly Jefferson

Colette Cywes Bentley

David Skurnik

Colette Cywes-Bentley

The disclosure relates, in part, to the use of compositions of poly N-acetylated glucosamine (PNAG), deacetylated PNAG (dPNAG), and antibodies and antibody fragments specific to PNAG in the prevention and treatment of filariasis.

Polysaccharide compositions for use in treating filariasis

The invention relates to the compositions of synthetic oligo-&#x3b2;-(1&#x2192;6)-2-amino-2-deoxy-D-glu-copyranosides conjugated to carriers, and methods for making and use same.

Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides

The invention relates to compositions of a deacetylated poly N-acetylated glucosamine (dPNAG) of Staphylococci. The dPNAG may be isolated from natural sources or synthesized de novo. The invention also relates to the use of dPNAG as a vaccine for inducing active immunity to infections caused by, other related coagulase-negative or coagulase-positive Staphylococci, and other organisms carrying the ica (intracellular adhesion) locus. The invention further provides methods of use for antibodies directed to dPNAG, particularly for inducing passive immunity to the same class of infections.

Polysaccharide vaccine for staphylococcal infections

The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such asPNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited toand. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited toand. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.

Poly-n-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof

The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.

Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof

The invention relates to the compositions of synthetic oligo-&#x3b2;-(1&#x2192;6)-2-amino-2-deoxy-D-glucopyranosides conjugated to carriers, and methods for making and use same.

Provided herein are methods and materials for diagnosing a subject's predisposition for pulmonary infection in a CF subject by detecting a pulmonary infection genetic marker. Pulmonary infection markers have been identified in the IL-1 gene cluster and may be useful in predicting CF disease progression and assessing a CF subject's response to therapy.

Method for determining predisposition to pulmonary infection

The invention relates to compositions of the capsular polysaccharide/adhesin (PS/A) of staphylococci. The PS/A may be isolated or synthesized and includes various modifications to the structure of native PS/A based on the chemical characterization of PS/A. The invention also relates to the use of the PS/A as a vaccine for inducing active immunity to infections caused by, other related coagulase-negative staphylococci and organisms carrying the ica (intracellular adhesin) locus, and to the use of antibodies directed to PS/A for inducing passive immunity to the same class of infections.

[object Object]

Methods and compositions relating to synthetic &#x3b2;-1,6 glucosamine oligosaccharides

Growing community of inventors

Brookline, MA, United States of America

Gerald B Pier